KR970011073B1 - Capsule composition for control of diseases of adult people containing perilla japonica oil - Google Patents

Capsule composition for control of diseases of adult people containing perilla japonica oil Download PDF

Info

Publication number
KR970011073B1
KR970011073B1 KR1019920013702A KR920013702A KR970011073B1 KR 970011073 B1 KR970011073 B1 KR 970011073B1 KR 1019920013702 A KR1019920013702 A KR 1019920013702A KR 920013702 A KR920013702 A KR 920013702A KR 970011073 B1 KR970011073 B1 KR 970011073B1
Authority
KR
South Korea
Prior art keywords
weight
oil
composition
capsule composition
acid
Prior art date
Application number
KR1019920013702A
Other languages
Korean (ko)
Other versions
KR940001898A (en
Inventor
현기영
박재호
윤여경
Original Assignee
주식회사 엘지화학
성재갑
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지화학, 성재갑 filed Critical 주식회사 엘지화학
Priority to KR1019920013702A priority Critical patent/KR970011073B1/en
Publication of KR940001898A publication Critical patent/KR940001898A/en
Application granted granted Critical
Publication of KR970011073B1 publication Critical patent/KR970011073B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535Perilla (beefsteak plant)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin

Abstract

Capsule composition for inhibiting adult disease contains more than 90wt% of perilla oil, 0.1-0.2wt% of tocopherol, 1-5wt% of soybean phospholipid, 0.1-1.0wt% of garlic oil, 0.05-0.2wt% of b-carotene and 0.01-0.2wt% of vitamin C. Capsule composition has an effect on inhibiting fatness, resisting thrombi and lowering cholesterol.

Description

들깨유를 주원료로 한 성인병 억제용 캡슐 조성물Capsule composition for inhibiting adult disease with perilla oil as main ingredient
본 발명은 들깨유를 주원료로 한 성인병 억제용 캡슐 조성물에 관한 것이다.The present invention relates to a capsule composition for inhibiting adult diseases, the main ingredient of perilla oil.
순환기계 질환은 유전적 요소, 정신적 스트레스, 운동부족 및 비만, 과량의 나트륨 섭취 등이 중요 요인이지만, 최근 경제성장에 따른 국민소득의 증가로 육식위주의 식생활 패턴으로 인한 포화 지방산, 콜레스테롤 섭취증가가 주요한 원인으로 대두되고 있다. 동물근원의 포화지방산과 콜레스테롤 섭취증가는, 혈장지질과 콜레스테롤 수준을 증가시킬 뿐 아니라, 결국 동맥벽의 평활근에 지방의 축적과 조직의 경화, 콜레스테롤 축적 또한 트롬복산(Thromboxane) A2에 의한 혈소판 응고등이 중요한 요인이 되고 있다. 그리인랜드의 에스키모인들이 혈전증이나 심근경색에 의한 사망율이 현저히 낮은 것은, 그들이 섭취하는 어류에 풍부한 에이코사펜타에노인산(EPA), 도코사헥사에노인산(DHA)에 기인한다는 보고가 발표된 이래, 고도의 불포화 지방산의 생리적 기능에 대한 많은 연구가 진행되어 왔다. 그 결과, 에이코사펜타에노인산은 아라키도닌산과 경쟁적으로 작용하여 트롬복산 A2 생합성을 저해함과 동시에 트롬복산 A3를 생합성하여 항혈전 효과를 나타내며, 혈장지질, 트리글리세라이드(Triglyceride), 저농도 단백지질(Low density lipoprotein), 그리고 LDL-콜레스테롤 수준도 저하시킨다는 몇몇 논문도 보고되기에 이르렀다(Nestel et al. 1987, Hwang et al. 1987, Puppione et al. 1987). 반면 이러한 고도의 불포화 지방산을 섭취할 경우 노화촉진, 각종질병의 유발등의 문제점 또한 적지 않으며, 장기적인 섭취로 지방간의 형성도 배제할 수 없다. 또한 어유로부터 EPA 정제가 쉽지 않고, 그나마 정제된 낮은 순도의 EPA 제제나 정제어유의 가격이 저렴하지 않기 때문에, 많은 사람들이 애용할 수 없었다.Circulatory disorders are due to genetic factors, mental stress, lack of exercise, obesity, and excessive sodium intake.However, the recent increase in national income caused by economic growth led to increased saturated fatty acid and cholesterol intake due to meat-oriented dietary patterns. It is emerging as a major cause. Increasing saturated fatty acid and cholesterol intake from animal sources not only increases plasma lipids and cholesterol levels, but also results in fat accumulation, hardening of tissues, and cholesterol accumulation in the smooth muscles of the arterial walls, as well as thromboxane A.2Platelet coagulation due to this is an important factor. Reportedly, Greenland's Eskimos have significantly lower mortality from thrombosis and myocardial infarction due to eicosapentaenophosphate (EPA) and docosahexaenophosphate (DHA), which are abundant in their fish. Since then, much research has been conducted on the physiological function of highly unsaturated fatty acids. As a result, eicosapentaenoic acid acts competitively with arachidonic acid, resulting in thromboxane A2 Thromboxane A while inhibiting biosynthesis3Several articles have also been reported that biosynthesis results in antithrombotic effects and also lowers plasma lipids, triglycerides, low density lipoproteins, and LDL-cholesterol levels (Nestel et al. 1987, Hwang). et al. 1987, Puppione et al. 1987). On the other hand, ingestion of these highly unsaturated fatty acids is also a problem of promoting aging and causing various diseases, and fatty liver formation cannot be ruled out in the long term. In addition, since EPA purification is not easy from fish oil and the price of purified low purity EPA preparations or refined fish oil is not cheap, many people cannot use it.
이에 본 발명자 등은 상기의 문제점을 해결하고자 연구한 결과, 알파-리놀레닌산(α-linolenic acid)이 체내에서 에이코사펜타에노인산, 도코사헥사에노인산으로 일부 전환될 수 있으며, 에이코사펜타에노인산, 도코사헥사에노인산 섭취시보다 체내에서 단백질 또는 세포막에 손상을 일으키는 말론디알데히드(Malondi-aldehyde)의 생성이 적다는 사실을 실험을 통하여 확인하였다.Therefore, the present inventors have studied to solve the above problems, alpha-linolenic acid (α-linolenic acid) can be partially converted to eicosapentaenoic acid, docosahexaenoic acid in the body, eico Experiments confirmed that the production of malondialdehyde (Malondi-aldehyde) that causes damage to proteins or cell membranes in the body than intake of sapentanoenoic acid, docosahexaenophosphate was confirmed through experiments.
알파-리놀레닌산은 분석시료에 따라 약간의 차이가 있으나 다가 불포화 지방산이 약 80%, 일가 불포화 지방산이 10 내지 14%, 포화지방산이 7 내지 10%로 함유된 들깨유에 약 50 내지 60%를 함유하고 있으며, 일부 우리나라 사람들은 들깨유를 성인병 치료를 위해 섭취해왔지만, 들깨유 특유의 냄새와 맛으로 인한 섭취가 불편하며, 동물실험에서 털이 빠지고, 색소침착, 비타민 결핍증상이 일부 문헌에서 보고되었다.Although alpha-linolenic acid differs slightly depending on the sample to be analyzed, it contains about 80% in perilla oil containing about 80% polyunsaturated fatty acid, 10-14% monounsaturated fatty acid, and 7-10% saturated fatty acid. Although some Koreans have consumed perilla oil for the treatment of adult diseases, it is inconvenient to consume perilla oil due to its unique smell and taste, and hair loss, pigmentation and vitamin deficiency symptoms have been reported in some literatures. .
이에 본 발명자들은 들깨유를 주원료로 하여 이러한 문제점을 최소화하며, 성인병 예방 및 치료하고 체내 지방대사를 원활히 하며, 휴대와 복용이 간편한 캡슐형태의 제제를 제조하기에 이르렀다.Accordingly, the present inventors have minimized these problems by using perilla oil as a main ingredient, preventing and treating geriatric diseases, smoothing the body's fat metabolism, and preparing a capsule-type preparation that is easy to carry and take.
본 발명은 들깨유 90중량% 이상, 토코페롤 0.1 내지 0.2중량%, 녹차 추출물 0.1 내지 0.5중량%, 대두인지질 1 내지 5중량%, 마늘오일 0.1 내지 1.0중량%, 베타카로틴 0.05 내지 0.2중량% 및 비타민 C 0.01 내지 0.2중량%를 함유하는 성인병억제용 캡슐조성물에 관한 것이다.The present invention is more than 90% by weight perilla oil, 0.1 to 0.2% by weight tocopherol, 0.1 to 0.5% by weight green tea extract, 1 to 5% by weight soybean phospholipid, 0.1 to 1.0% by weight garlic oil, 0.05 to 0.2% by weight beta carotene and vitamins It relates to a capsule composition for inhibiting adult disease containing C 0.01 to 0.2% by weight.
이하 본 발명을 상세히 설명하면 다음과 같다. 들깨유는 알파-리놀레닌산을 함유하며 불포화도가 90%이상으로서, 상온에서도 산화가 쉽게 일어나며 따라서 항산화제가 우선적으로 요구된다. 본 발명에서는 항산화제로써 알파-토코페롤과 자연중에 항산화력을 나타내는 차 추출물을 이용하였다. 알파-토코페롤은 현재까지 가장 잘 알려진 항산화제로써 체내에서 과산화지질 형성을 억제하며, 결과 노화방지나 과산화지질에 의한 암발생을 억제한다. 일반적으로 불포화 지방산 섭취량 단위 g당 0.4 내지 0.6mg이 요구되며 장에서의 흡수율과 알파-토코페롤 자체의 산화를 고려하여 본 발명에서는 0.10 내지 0.20%를 사용하였다.Hereinafter, the present invention will be described in detail. Perilla oil contains alpha-linolenic acid and has an unsaturation of 90% or more, so oxidation easily occurs at room temperature, and therefore, an antioxidant is required first. In the present invention, as an antioxidant, alpha-tocopherol and tea extracts showing antioxidant power in nature were used. Alpha-tocopherol is the best known antioxidant to date, which inhibits the formation of lipid peroxide in the body. As a result, it inhibits the aging and the cancer caused by lipid peroxide. In general, 0.4 to 0.6 mg per g of unsaturated fatty acid intake is required, and 0.10 to 0.20% was used in the present invention in consideration of absorption in the intestine and oxidation of alpha-tocopherol itself.
또한 녹차 추출 성분중에 함유된 탄닌 성분인 카테친(Catechin)도 항암, 항산화 작용을 나타낼 뿐 아니라 체내에서 혈중지질, 콜레스테롤 수준을 낮추어주므로 본 발명에서는 약 0.1 내지 0.5%의 녹차 추출물(일본/삼공제약, Sanfood 유성)을 부가하였다. 녹차 추출물 제제(일본/삼공제약 Sanfood, 유성)는 페놀(Phenol)계 열 카테친 이외에 토코페롤, 구연산도 일부 함유하고 있으며, 0.2% 수준을 사용시 충분한 항산화작용을 나타내었고 그외 다른 여러 생리적인 효과가 기대된다. 그리고 장내에서 지방의 흡수를 촉진하고, 혈액내 지질의 용해, 지방간 형성감소 효과를 위해서 대두 인지질(60%)을 약 1 내지 5% 첨가하였으며 대두 인지질 첨가에 따른 리놀렌산(linoleic acid)함량증가에 따라 체내 필수지방산 공급은 물론 혈중 콜레스테롤 저하작용의 동시 효과를 기대할 수 있다. 그리고 지방산의 산화로 인한 과산화지질을 억제하고 암발생을 예방하기 위하여 비타민 A의 전구물질인 베타카로틴(β-carotene)을 (활성 30% 유성)을 0.05 내지 0.2% 첨가하였다.In addition, catechin (Catechin), a tannin component contained in the green tea extract, also exhibits anti-cancer and antioxidant activities, and lowers blood lipid and cholesterol levels in the body. Thus, the present invention provides about 0.1-0.5% green tea extract (Japan / Sampo Pharmaceutical, Sanfood oily) was added. The green tea extract formulation (Japan / Sanpo Pharmaceutical Sanfood, Oily) contains not only phenolic catechins but also some tocopherols and citric acid. When the 0.2% level is used, it shows sufficient antioxidant activity and many other physiological effects are expected. . Soybean phospholipid (60%) was added about 1 to 5% to promote the absorption of fat in the intestine, to dissolve lipids in the blood, and to reduce the formation of fatty liver, and to increase linoleic acid content with soybean phospholipid. In addition to the supply of essential fatty acids in the body can be expected to have a simultaneous effect of lowering blood cholesterol. In addition, beta carotene (β-carotene) (active 30% oil) was added 0.05 to 0.2% to inhibit lipid peroxide caused by oxidation of fatty acids and prevent cancer.
β-카로틴 구조β-carotene structure
또한 암을 예방하는 기능이 있으며, 체내 면역기능을 강화하며, 유해한 세균을 살균하는 것으로 알려진 알리신(allicine)을 함유하는 마늘오일은 혈압을 낮추고 혈전 용해작용이 있어 성인병 예방 및 치료에 효과가 있다. 따라서 본 발명 조성물에서는 마늘오일을 0.1 내지 1.0% 첨가하였다.In addition, it has a function of preventing cancer, enhances immune function in the body, and garlic oil containing allicin (allicine), which is known to sterilize harmful bacteria, lowers blood pressure and has a thrombolytic effect, which is effective in preventing and treating adult diseases. Therefore, in the composition of the present invention, 0.1 to 1.0% garlic oil was added.
각 구성성분의 작용효과 등을 고려해볼때 본 발명에 따른 캡슐조성물의 대표적인 구성성분 및 비율은 아래와 같고, 이하 실시예에서는 이러한 성인병 예방용 조성물을 이용하였다.Considering the effects and the effects of each component, the representative components and ratios of the capsule composition according to the present invention is as follows, in the following examples, such a composition for preventing adult diseases was used.
성인병 예방용 조성물 가운데 비타민 C는 괴혈병 유발 방지 및 지방의 적절한 산화등의 목적으로 첨가하였다.In the composition for preventing adult diseases, vitamin C was added for the purpose of preventing scurvy and proper oxidation of fat.
이상에서 설명한 본 발명 조성물을 제조, 캡슐화와 실험동물에 적용하였으며 실시예에 의거하여 구체적으로 설명하면 다음과 같다.The composition of the present invention described above was applied to the preparation, encapsulation and laboratory animals and described in detail based on examples.
[실시예 1]Example 1
압착착유한 들깨유를 흡입기와 Whatman 여과지를 이용하여 식용유속에 존재하는 검질을 제거한 후 0.2%의 녹차 추출물과 대두인지질을 첨가하면서 60℃로 가온 교반하였다.Pressurized perilla oil was removed by using an inhaler and Whatman filter paper to remove the gums present in the edible oil, followed by stirring at 60 ° C. while adding 0.2% green tea extract and soybean phospholipid.
[실시예 2]Example 2
균일상을 확인하고 35℃ 내지 40℃로 감온한 후 알파-토코페롤을 참가 10분간 교반하였으며 다시 0.1중량%의 베타카로틴, 0.5중량%의 마늘 추출물(오일), 0.05중량%의 비타민 C 분말을 첨가, 균일상이 될때까지 교반, 조성물을 제조하였다.After confirming the homogeneous phase and reducing the temperature to 35 ° C. to 40 ° C., the alpha-tocopherol was stirred for 10 minutes, followed by addition of 0.1% of beta carotene, 0.5% of garlic extract (oil) and 0.05% of vitamin C powder. It stirred until it became a uniform phase, and manufactured the composition.
[실시예 3]Example 3
쥐의 체중이 약 100g인 4주령 스프라그-다우리(Sprague-Dawly) 암컷 20마리를 5마리씩 4군으로 나누어 조단백질 20.0%, 칼슘 0.6%, 인 0.4%, 조지방 3.0%, 무기질 10.1%, 섬유질 10.0%를 함유한 기본 고형사료를 일주일간 자유급식 적응시켰다.20 female Sprague-Dawly females weighing about 100 g were divided into 4 groups of 5 rats, crude protein 20.0%, calcium 0.6%, phosphorus 0.4%, crude fat 3.0%, mineral 10.1%, and fiber. Basic solid feed containing 10.0% was free-adapted for one week.
[실시예 4]Example 4
4군중 2군은 고형사료로 계속 자유급식시켰으며, 나머지 2군은 기본 고형사료를 부분 파쇄한 후 기본 고형사료와 본 발명 조성물, 카제인 나트륨을 각각 80%, 15%, 5% 비율로 혼합하여 자유급식시켰다.Group 2 of 4 groups continued to feed freely with solid feed, and the remaining two groups partially crushed the basic solid feed, and then mixed the basic solid feed, the composition of the present invention, and casein sodium at a ratio of 80%, 15%, and 5%, respectively. Free meals.
[실시예 5]Example 5
실험 4주에 대조구, 첨가구 각각 5마리 쥐의 소변으로부터 말론디알데하이드를 측정해 본 결과, 대조구 첨가구에서 각각 평균 57.65, 56.93㎍/g(MDA/무게)로 나타나 별차이가 없었으며, 이는 어유섭취시 발생되는 다량의 과산화물(68.00㎍/g)이 생성되지 않는 장점을 실험을 통하여 확인할 수 있었다.At 4 weeks of the experiment, malondialdehyde was measured from the urine of 5 rats of the control and the control group, respectively, and the average of 57.65 and 56.93 µg / g (MDA / weight) of the control group showed no difference. It was confirmed through experiments that a large amount of peroxide (68.00㎍ / g) generated when ingesting fish oil was not produced.
[실시예 6]Example 6
5주 급여후 대조구 5마리와 조성물 첨가구 5마리의 혈장 콜레스테롤을 분석하였으며 콜레스테롤 함량은 대조구에서 평균 66㎎/100㎖인데 비해, 조성물 첨가구에서는 평균 50㎎/100㎖로 나타났다.Plasma cholesterol was analyzed in 5 control and 5 composition added groups after 5 weeks of feeding. The cholesterol content was 66mg / 100ml in the control group, compared with 50mg / 100ml in the composition added group.
이러한 결과는 들깨유만을 급여한 쥐에서의 혈중 콜레스테롤(55㎎/100㎖)보다 낮게 나타났는데, 이는 식물근원의 불포화 지방산에 녹차 추출물의 카테친, 마늘 추출물의 혈중 콜레스테롤 저하의 복합된 상승 효과로 보여진다.These results were lower than the blood cholesterol (55mg / 100ml) in rats fed only perilla oil, which is a synergistic effect of the hypocholesterolemic effect of catechin and garlic extract of green tea extract on unsaturated fatty acids of plant origin. Lose.
[실시예 7]Example 7
항혈전과 관련하여 실험 16중에 호른스트라(Hornstra)법에 의하여 쥐의 출혈시간을 측정하였다. 대조구에서 지혈시간이 평군 119초였으나 첨가구에서는 138초로 나타나 항혈액 응고를 보여주었다. 이러한 결과는 어유 섭취시(169)와 약간의 차이를 보여주지만, 어유의 장시간 섭취에 따른 뇌출혈의 위험이나, 사고시 지혈지연현상을 감안하면 큰 장점으로 혈전증 예방가능성을 강력히 나타내어 준다.In relation to antithrombosis, the bleeding time of rats was measured by the Hornstra method during the experiment 16. Hemostatic time was 119 seconds in the control group, but 138 seconds in the control group, indicating anti-blood coagulation. These results show a slight difference from the consumption of fish oil (169), but considering the risk of cerebral hemorrhage due to prolonged intake of fish oil, or hemostasis delay in an accident, it shows strongly the possibility of preventing thrombosis.
[실시예 8]Example 8
실험 16주, 간과 신장조직에 알파-리놀레닌산의 EPA, DHA로의 전환을 확인하였다. 간과 신장조직의 총지질을 추출한 뒤 각 인지질군을 TLC 분석으로 분리 추출하여, 조직 세포막의 높은 비율을 차지하고 있는 포스파티딜 콜린(phosphatidyl choline)과 포스파티딜에탄올아민(phosphatidyl ethanolamine)을 분리하여 각 인지질의 지방산 조성을 분석하였으며 그 결과는 다음과 같다.At 16 weeks of experiment, liver and kidney tissues were confirmed to convert alpha-linolenic acid to EPA and DHA. After extracting total lipids of liver and kidney tissue, each phospholipid group was extracted and extracted by TLC analysis. The results are as follows.
[ 표 1 간조직 인지질, Phosphatidyl choline과 phosphatidyl ethanolamine의 지방산 조성]Table 1 Fatty acid composition of hepatic phospholipids, phosphatidyl choline and phosphatidyl ethanolamine
간조직의 경우에 대조구에서 미량으로 나타난 에이코사펜타에노인산이, 조성물 첨가구에서 두 인지질군 각각 13.5%, 11.5%로 증가, 본 조성물 섭취에 따른 조직내에서의 높은 3계열 에이코사노이드(Eicosanoid) 생성 가능성을 보여주었으며, 반면 아라카도닌단의 함량은 대조구 두 인지질군의 각각 23.6%, 20.1%에서 조성물 첨가구시 6.2%, 5.7%로 나타나 아라키도닌산 생성대사의 저해 내지 차단, 성인병 예방의 가능성을 확인할 수 있었다. 도코사헥사에노인산 역시 조성물 첨가구에서 두 인지질군 각각 4.5%, 8.2%로 증가, 결국 알파-리놀레닌산의 에이코사펜타에노인산, 도코사헥사에노인산으로 전환을 보여주었으며 조직중에 존재하는 증가된 에이코사 펜타에도민산, 도코사헥사에노인산은 아리키도닌산 대사를 저해 내지 차단할 뿐만 아니라 트롬복산 A3생성의 기질로 작용하여 성인병 억제 가능성을 보여준다. 실험 16주에 신장조직의 인지질 Phosphatidyl choline과 Phosphatidyl ethanolamine의 지방산 조성을 분석하였으며 그 결과는 다음과 같다.In the case of liver tissue, eicosapentaenoic acid showed a trace amount in the control group, increased to 13.5% and 11.5% of the two phospholipid groups, respectively. ), Whereas the content of arachonindan was 23.6% and 20.1% of the two phospholipid groups, 6.2% and 5.7%, respectively, when the composition was added, and the possibility of inhibiting or blocking arachidonic acid production metabolism and preventing adult diseases. Could confirm. Docosahexaenophosphate also increased to 4.5% and 8.2% for the two phospholipid groups, respectively, and eventually showed conversion of alpha-linolenic acid to eicosapentaenoic acid and docosahexaenoic acid. The increased eicosapentaenoic acid and docosahexaenoic acid present present not only inhibit or block the arkidonic acid metabolism, but also act as a substrate for thromboxane A 3 production, demonstrating the potential for inhibiting geriatric disease. Fatty acid composition of phospholipid Phosphatidyl choline and Phosphatidyl ethanolamine in renal tissue was analyzed at 16 weeks.
[표 2 신장조직의 인지질 Phosphatidyl choline과 Phosphatidyl ethanolamine의 지방산 조성][Table 2 Fatty Acid Composition of Phospholipid Phosphatidyl Choline and Phosphatidyl Ethanolamine in Kidney Tissue]
신장조직 인지질의 지방산 조성도 간조직처럼, 리놀레닌산, 에이코사펜타에노인산, 도코사헥사에노인산은 증가하는 경향을 나타내었고, 아라키도닌산은 감소하는 경향을 나타내어 에이코사노이드 생성에 변화를 초래, 결국 성인병 억제 가능성을 보여주었다.The fatty acid composition of renal tissue phospholipids, like liver tissue, showed a tendency to increase linolenic acid, eicosapentaenoic acid and docosahexaenoic acid, while arachidonic acid tended to decrease, resulting in changes in eicosanoid production. And eventually showed the possibility of suppressing geriatric disease.
[실시예 9]Example 9
본 발명 조성물의 비만 방지 효과를 실험하기 위하여 몸무게가 63 내지 70㎏ 사이의 비만 여성 10명에서 1일 복용량을 표 3에서와 같이 변화시키면서 2개월간 복용시켰다. 표 3의 증감율에서와 같이 6명의 비만여성에게서 2 내지 14%의 체중 감소현상이 있었고, 나머지 4명에서는 변화가 없었다.In order to test the anti-obesity effect of the composition of the present invention, the body weight of 10 obese women between 63 and 70 kg was taken for 2 months while changing the daily dose as shown in Table 3. As shown in Table 3, there were 2 to 14% weight loss in 6 obese women and no change in the other 4 obese women.
[표 3 본 발명 조성물의 체중에 대한 영향]TABLE 3 Influence on the weight of the composition of the present invention
이는 식물근원의 불포화 지방산이, 체내에서 트리글리세라이드 합성을 저해하고 비타민 C, 구연산, 카테친의 상승작용으로 인해 본 발명 조성물이 비만 방지효과를 가짐을 보여주었다.This showed that the unsaturated fatty acid of plant origin inhibits triglyceride synthesis in the body and the composition of the present invention has an anti-obesity effect due to the synergy of vitamin C, citric acid and catechin.
따라서 본 조성물 제제를 적절히 섭취하므로서 비만억제, 항혈전, 콜레스테롤 저하의 성인병 예방, 치료효과를 얻을 수 있을 뿐 아니라 어유를 정제하여 만든 EPA 제제보다 과산화 지질 형성에 따른 부작용을 줄일 수 있다. 뿐만 아니라 필수 지방산인 리놀렌산과 리놀렌산을 적절히 공급하므로서, 성장저해, 피부조악등의 필수 지방산 결핍증을 억제함과 동시에 카테친, 플라보노이드, 그리고 베타카로틴의 항암, 항산화등의 동시 효과도 기대할 수 있다.Therefore, by properly ingesting the formulation of the present composition can not only prevent obesity, antithrombotic, lower cholesterol and treatment of cholesterol, but also reduce side effects due to lipid peroxide formation than EPA preparations made by refining fish oil. In addition, by properly supplying the essential fatty acids linolenic acid and linolenic acid, it is possible to inhibit the growth of the fatty acid deficiency such as skin coarse, and at the same time anti-cancer, antioxidant and anti-cancer of catechin, flavonoids and beta-carotene.

Claims (3)

  1. 들깨유 90중량% 이상, 토코페롤 0.1 내지 0.2중량%, 녹차 추출물 0.1 내지 0.5중량%, 대두인지질 1 내지 5중량%, 마늘오일 0.1 내지 1.0중량%, 베타카로틴 0.05 내지 0.2중량% 및 비타민 C 0.01 내지 0.2중량%를 함유하는 비만억제제 캡슐 조성물.Perilla oil 90% or more, 0.1 to 0.2% by weight of tocopherol, 0.1 to 0.5% by weight of green tea extract, 1 to 5% by weight of soybean phospholipid, 0.1 to 1.0% by weight of garlic oil, 0.05 to 0.2% by weight of beta carotene and 0.01 to 0.01% of vitamin C Obesity inhibitor capsule composition containing 0.2% by weight.
  2. 들깨유 90중량% 이상, 토코페롤 0.1 내지 0.2중량%, 녹차 추출물 0.1 내지 0.5중량%, 대두인지질 1 내지 5중량%, 마늘오일 0.1 내지 1.0중량%, 베타카로틴 0.05 내지 0.2중량% 및 비타민 C 0.01 내지 0.2중량%를 함유하는 항혈전제 캡슐 조성물.Perilla oil 90% or more, 0.1 to 0.2% by weight of tocopherol, 0.1 to 0.5% by weight of green tea extract, 1 to 5% by weight of soybean phospholipid, 0.1 to 1.0% by weight of garlic oil, 0.05 to 0.2% by weight of beta carotene and 0.01 to 0.01% of vitamin C An antithrombotic capsule composition containing 0.2% by weight.
  3. 들깨유 90중량% 이상, 토코페롤 0.1 내지 0.2중량%, 녹차 추출물 0.1 내지 0.5중량%, 대두인지질 1 내지 5중량%, 마늘오일 0.1 내지 1.0중량%, 베타카로틴 0.05 내지 0.2중량% 및 비타민 C 0.01 내지 0.2중량%를 함유하는 콜레스테롤 저하제 캡슐 조성물.Perilla oil 90% or more, 0.1 to 0.2% by weight of tocopherol, 0.1 to 0.5% by weight of green tea extract, 1 to 5% by weight of soybean phospholipid, 0.1 to 1.0% by weight of garlic oil, 0.05 to 0.2% by weight of beta carotene and 0.01 to 0.01% of vitamin C A cholesterol lowering capsule composition containing 0.2% by weight.
KR1019920013702A 1992-07-30 1992-07-30 Capsule composition for control of diseases of adult people containing perilla japonica oil KR970011073B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920013702A KR970011073B1 (en) 1992-07-30 1992-07-30 Capsule composition for control of diseases of adult people containing perilla japonica oil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920013702A KR970011073B1 (en) 1992-07-30 1992-07-30 Capsule composition for control of diseases of adult people containing perilla japonica oil

Publications (2)

Publication Number Publication Date
KR940001898A KR940001898A (en) 1994-02-16
KR970011073B1 true KR970011073B1 (en) 1997-07-07

Family

ID=19337261

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013702A KR970011073B1 (en) 1992-07-30 1992-07-30 Capsule composition for control of diseases of adult people containing perilla japonica oil

Country Status (1)

Country Link
KR (1) KR970011073B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941672A1 (en) * 1998-03-07 1999-09-15 Heinz D. Dr. Jodlbauer Nutritional supplement
KR100690980B1 (en) * 1999-07-16 2007-03-12 정종문 A drink decomposing cholesterol and a formulation decomposing the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941672A1 (en) * 1998-03-07 1999-09-15 Heinz D. Dr. Jodlbauer Nutritional supplement
KR100690980B1 (en) * 1999-07-16 2007-03-12 정종문 A drink decomposing cholesterol and a formulation decomposing the same

Also Published As

Publication number Publication date
KR940001898A (en) 1994-02-16

Similar Documents

Publication Publication Date Title
Cottrell Introduction: nutritional aspects of palm oil
Sanders et al. The Influence of Different Types of ω 3 Polyunsaturated Fatty Acids on Blood Lipids and Platelet Function in Healthy Volunteers
Yang et al. Composition and physiological effects of sea buckthorn (Hippophae) lipids
Hall Uniformity of human milk
US5120760A (en) Treating tardive dyskinesia with essential fatty acid compositions
Tebib et al. Dietary grape seed tannins affect lipoproteins, lipoprotein lipases and tissue lipids in rats fed hypercholesterolemic diets
CA2101274C (en) Microbial oil mixtures and uses thereof
AU764699B2 (en) Conjugated linoleic acid compositions
CA2164291C (en) Methods and pharmaceutical compositions useful for treating neurological disorders
Rabasco Álvarez et al. Lipids in pharmaceutical and cosmetic preparations
CA2595914C (en) Production and use of an antioxidant extract from crypthecodinium sp.
Meluzzi et al. Effects of dietary vitamin E on the quality of table eggs enriched with n-3 long-chain fatty acids
US5562913A (en) Formulation for use in smokers
ES2289097T3 (en) Composition for the prevention of osteoporosis consistent of a combination of isoflavones and polyinsaturated fat acids.
Meydani et al. Effect of long-term fish oil supplementation on vitamin E status and lipid peroxidation in women
FI76678B (en) Foerfarande foer framstaellning av lipidiemulsion avsedd foer oral, enteral eller paranteral naering.
EP0960567B1 (en) Fat based food products
CA1337548C (en) Fatty acid composition
Salari et al. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis
US5415879A (en) Method of reducing heart related disease in humans using eggs having relatively high percentage of long chain fatty acids
Stuchlík et al. Vegetable lipids as components of functional foods
Van Elswyk Comparison of n–3 fatty acid sources in laying hen rations for improvement of whole egg nutritional quality: a review
EP1662904B1 (en) Compositions containing as the active ingredient componantes from salvia sclarea seed
US8124142B2 (en) Cranberry seed oil, cranberry seed flour and a method for making
CN1073825C (en) Food composition containing balancing agent for 'omega'-6 and 'omega'-3 unsaturated fatty acids

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee